Associated tags: Century, Ink, B cell, Genetic engineering, IPSC, Therapy, Stem cell, Cancer, Pharmaceutical industry, Glossary, Security (finance), Patient, Conference
Locations: PHILADELPHIA, PA, US, CAR, CHICAGO, IL, COOLEY, UNITED STATES
Cancer,
Investment,
Cell,
Research,
Gene editing,
Research and development,
Ink,
Computational biology,
Myasthenia gravis,
CRS,
Science,
Protein engineering,
Administration,
Rejection,
IPSC,
CD19,
Autoimmune disease,
Bristol Myers Squibb,
Patient,
Acquisition,
Pharming,
NHL,
Century,
Malignancy,
BMS,
AACR,
SLE,
Therapy,
Lymphoid leukemia,
GAAP,
BCMA,
NK,
Pharmaceutical industry Century’s core Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells.
Key Points:
- Century’s core Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells.
- In April 2024, the Company announced plans to expand clinical development of CNTY-101 into additional autoimmune disease indications beyond SLE.
- In the second half of 2024, Century intends to submit additional regulatory filings for CNTY-101 in autoimmune disease indications with limited current treatment options and high unmet need.
- Century plans to share additional data from its Phase 1 ELiPSE-1 trial in R/R non-Hodgkin lymphoma (NHL) at the upcoming ASCO Annual Meeting, being held May 31-June 4, 2024, in Chicago, IL.
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
Key Points:
- PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
Panel titled “iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies” on Tuesday, April 30, 2024, at 3:30pm ET
A replay of the events will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the events.
NK,
Sale,
Cancer,
LLP,
Lazard,
Investment,
News,
Safety,
Security (finance),
Ink,
Myasthenia gravis,
Research,
Exchange,
Haematopoiesis,
Lymphoma,
IPSC,
CD19,
Autoimmune disease,
Patient,
Acquisition,
Pharming,
NHL,
Inflammation,
BofA Securities,
SLE,
Clinical trial,
Therapy,
Lymphoid leukemia,
Autoimmunity,
BCMA PHILADELPHIA, April 11, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned clinical trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024. Century plans to pursue additional autoimmune disease indication regulatory filings in 2024. Century’s increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors. Concurrently, Century announced pipeline and platform enhancements through the acquisition of Clade Therapeutics, Inc. (“Clade”), a privately-held biotech company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, with a focus on iPSC-derived αβ T cells. The acquisition brings additional iPSC-focused pipeline programs and technology to Century spanning across cancer and autoimmune diseases.
Key Points:
- Century plans to pursue additional autoimmune disease indication regulatory filings in 2024.
- Century’s increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors.
- The acquisition brings additional iPSC-focused pipeline programs and technology to Century spanning across cancer and autoimmune diseases.
- With support from a distinguished group of investors, coupled with the acquisition of Clade, we are poised for continued success,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century.
Computational biology,
Malignancy,
Canadian Aviation Regulations,
Gene editing,
Bone disease,
Cell,
Hook effect,
CXCR4,
Enfortumab vedotin,
Synthetic biology,
Patient,
Neoplasm,
Epitope,
Differentiable function,
Ink,
PBMC,
Protein engineering,
HLA,
Science,
Cytotoxicity,
AACR,
Phenotype,
Therapy,
IPSC,
Skin,
Inflammation,
Prognosis,
Carcinogenesis,
Rejection,
CD22,
VHH,
Poster,
NK,
Century,
Autoimmunity,
Bone marrow,
Engineering,
CD19,
Vaccine PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
Key Points:
- PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
- This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
- These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
- In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
Key Points:
- PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
- A replay of the event will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the event.
EGFR,
Gene editing,
Cell,
Immunotherapy,
Patient,
BMS,
SLE,
Bristol Myers Squibb,
Protein engineering,
IND,
Investment,
Therapy,
CRS,
Lymphoma,
Research,
Computational biology,
ASH,
Pharming,
Investigational New Drug,
IPSC,
Cancer,
Safety,
Inflammation,
Food,
Cetuximab,
AACR,
Research and development,
GAAP,
NK,
FDA,
Administration,
Ink,
MBA,
Abstract,
Society,
Rejection,
Century,
Autoimmunity,
Pharmaceutical industry PHILADELPHIA, March 14, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today reported financial results and business highlights for the full year ended December 31, 2023.
Key Points:
- In December 2023, Century presented initial clinical data from the Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory (r/r) B-cell lymphomas.
- Data showed that CNTY-101 was well-tolerated at Dose Level 1 (100 million cells) in high-risk, heavily pretreated R/R B-cell lymphoma patients.
- Net Loss: Net loss was $136.7 million for the year ended December 31, 2023, compared to $131.0 million for the year ended December 31, 2022.
- The Company expects full year generally accepted accounting principles (GAAP) operating expenses to be between $135 million and $145 million.
PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.
Key Points:
- PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in six posters at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, CA.
- The upcoming abstracts highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, protein engineering and computational biology.
- Additionally, the Company will share new preclinical data on additional Allo-Evasion™ edits that could further support Century’s multi-dosing strategy.
- Details of the poster presentations are as follows:
Full abstracts are currently available through the AACR conference website.
Retrieved on:
Thursday, February 1, 2024
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.
Key Points:
- PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.
- A replay of the event will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the event.
Retrieved on:
Saturday, December 9, 2023
Exposition,
Tumor microenvironment,
Bone marrow,
Dose,
Cytokine release syndrome,
IPSC,
Tissue,
Pharming,
DNA,
Society,
Therapy,
DdPCR,
Follicular lymphoma,
Serum,
Interleukin 2,
Event,
ASH,
Neurotoxicity,
Poster,
Century,
Ink,
Cell,
Patient,
Malignancy,
Webcast,
Allotransplantation,
Lymphoma,
Science,
Pharmaceutical industry PHILADELPHIA, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced the presentation of initial clinical data from a single-patient case study which Century believes support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12 in San Diego. The poster, titled, “Multiple Doses of CNTY-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study”, is available on the Scientific Resources page of the Company’s website.
Key Points:
- “We are thrilled that the initial clinical evidence for CNTY-101 provides support for the potential for Allo-Evasion™ to enable a multi-dosing regimen without the need for continued lymphodepletion.
- Cycles one and two included three days of lymphodepletion (LD), whereas cycles three through seven were given with no LD.
- Importantly, tumor microenvironment initial analyses demonstrated a vigorous increase in T cells within 8 days of the 1st CNTY-101 cell infusion.
- The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website.
Retrieved on:
Wednesday, December 6, 2023
Autoimmunity,
IPSC,
Society,
Therapy,
Inflammation,
Lymphoma,
Event,
Webcast,
Patient,
CD19,
Pharmaceutical industry In addition to updated preliminary clinical data as of a more recent data cutoff date from a case study being featured in a poster presentation at the 65th American Society of Hematology Annual Meeting, the Company will also present additional results from patients treated at Dose Level 1 (100 million cell dose), as well as preliminary data from patients treated at Dose Level 2 (300 million cell dose).
Key Points:
- In addition to updated preliminary clinical data as of a more recent data cutoff date from a case study being featured in a poster presentation at the 65th American Society of Hematology Annual Meeting, the Company will also present additional results from patients treated at Dose Level 1 (100 million cell dose), as well as preliminary data from patients treated at Dose Level 2 (300 million cell dose).
- The Company will also discuss its planned Phase 1 trial, including supporting preclinical data, for CNTY-101 in systemic lupus erythematosus, the first autoimmune and inflammatory disease indication for CNTY-101.
- The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website.
- Alternatively, the conference call may be accessed through the following:
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.centurytx.com approximately 24 hours after the conference call and will be available for 90 days following the call.
